Ocular Therapeutix Inc. Announces Inducement Grants Under Nasdaq Listing Rule
1. Strategic Moves to Attract Talent
In a significant move to strengthen its workforce, Ocular Therapeutix, Inc. (NASDAQ: OCUL) announced on April 14, 2026, the granting of inducement awards to six newly hired non-executive employees, as well as to Mr. Jerome M. Gangitano, the company’s new Senior Vice President of CMC Technical Operations. This initiative is part of Ocular’s strategy to attract top-tier talent and is conducted in accordance with Nasdaq Listing Rule 5635(c)(4).
2. Details of the Inducement Awards
The inducement equity awards were effective as of April 8, 2026, for the six newly hired non-executive employees and April 13, 2026, for Mr. Gangitano. Here’s a breakdown of the equity awards:
Non-Executive Employees
- Total Shares: 46,425 shares through non-statutory stock option awards.
- Additional Shares: 15,275 shares via restricted stock unit awards.
- Exercise Price: $8.42 per share, matching the closing price of Ocular’s common stock on the effective date.
Jerome M. Gangitano
- Total Shares: 300,000 shares through a non-statutory stock option award.
- Additional Shares: 100,000 shares via restricted stock unit awards.
- Exercise Price: $8.86 per share, aligned with the closing price of Ocular’s common stock on the grant date.
Vesting Schedule
All stock option awards have a ten-year term and are set to vest over four years. Specifically, 25% of the shares will vest on the one-year anniversary of the grant date, with the remainder vesting in equal monthly installments over the subsequent three years, contingent on the recipient's continued service. The restricted stock unit awards will vest over three years, with equal annual installments on the first, second, and third anniversaries of the grant date.
3. Ocular Therapeutix: A Commitment to Innovation
Ocular Therapeutix is recognized as an integrated biopharmaceutical company dedicated to transforming the retina experience. Its investigational product candidate, AXPAXLI™ (OTX-TKI), is currently undergoing Phase 3 clinical trials for conditions such as wet age-related macular degeneration and diabetic retinal disease, including non-proliferative diabetic retinopathy.
The company’s proprietary ELUTYX™ bioresorbable hydrogel technology is a cornerstone of its pipeline, which also includes DEXTENZA®, an FDA-approved corticosteroid for treating ocular inflammation and pain, as well as OTX-TIC, an investigational product candidate aimed at treating open-angle glaucoma or ocular hypertension.
4. Conclusion
Ocular Therapeutix’s recent inducement grants represent a strategic investment in human capital, positioning the company for future growth and innovation in the biopharmaceutical sector. With a robust pipeline and a commitment to redefining the retina experience, Ocular continues to reinforce its presence in the industry, making it a company to watch in the coming years.
